ENTERIC COATED ASA DAILY LOW DOSE TABLET (DELAYED-RELEASE)

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ACETYLSALICYLIC ACID

から入手可能:

PHARMASCIENCE INC

ATCコード:

B01AC06

INN（国際名）:

ACETYLSALICYLIC ACID

投薬量:

81MG

医薬品形態:

TABLET (DELAYED-RELEASE)

構図:

ACETYLSALICYLIC ACID 81MG

投与経路:

ORAL

パッケージ内のユニット:

7/30/120/150/180/255/300/360/365/500/1000

処方タイプ:

OTC

治療領域:

SALICYLATES

製品概要:

Active ingredient group (AIG) number: 0101169013; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2017-10-21

製品の特徴

PRODUCT MONOGRAPH
ENTERIC COATED ASA DAILY LOW DOSE
Acetylsalicylic Acid Delayed-release Tablets, USP
81 mg
Analgesic, anti-inflammatory, antipyretic and
Platelet aggregation inhibitor
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
DATE OF REVISION:
March 08, 2017
SUBMISSION CONTROL NUMBER: 199017
_ENTERIC COATED ASA DAILY LOW DOSE Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................9
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
SPECIAL HANDLING INSTRUCTIONS
.......................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II : SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................1